Emerging personalized approaches for the management of advanced urothelial carcinoma

Che Kai Tsao, Benjamin A. Gartrell, William K. Oh, Matthew D. Galsky

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Urothelial carcinoma of the bladder comprises a spectrum of illnesses ranging from nonmuscle-invasive to muscle-invasive to advanced/metastatic disease. Each of these clinical states is characterized by a unique pathogenesis, prognosis and approach to treatment. However, given the heterogeneity of urothelial carcinoma, differences in biology and outcomes exist not only among these clinical states but also within each state. Personalized medicine, also commonly referred to as individualized or stratified medicine, offers the potential to optimize treatment for a given patient, based on the ability to accurately predict prognosis, response to treatment and tolerability of treatment. This review will discuss recent efforts, current challenges and future opportunities, for the personalized management of urothelial carcinoma.

Original languageEnglish (US)
Pages (from-to)1537-1543
Number of pages7
JournalExpert Review of Anticancer Therapy
Volume12
Issue number12
DOIs
StatePublished - Dec 2012
Externally publishedYes

Fingerprint

Carcinoma
Precision Medicine
Therapeutics
Urinary Bladder
Medicine
Muscles

Keywords

  • biomarker
  • bladder cancer
  • chemotherapy
  • neoadjuvant therapy
  • personalized medicine
  • urothelial carcinoma

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Emerging personalized approaches for the management of advanced urothelial carcinoma. / Tsao, Che Kai; Gartrell, Benjamin A.; Oh, William K.; Galsky, Matthew D.

In: Expert Review of Anticancer Therapy, Vol. 12, No. 12, 12.2012, p. 1537-1543.

Research output: Contribution to journalArticle

Tsao, Che Kai ; Gartrell, Benjamin A. ; Oh, William K. ; Galsky, Matthew D. / Emerging personalized approaches for the management of advanced urothelial carcinoma. In: Expert Review of Anticancer Therapy. 2012 ; Vol. 12, No. 12. pp. 1537-1543.
@article{000a6f6232554a1e992cdd16d62dc65c,
title = "Emerging personalized approaches for the management of advanced urothelial carcinoma",
abstract = "Urothelial carcinoma of the bladder comprises a spectrum of illnesses ranging from nonmuscle-invasive to muscle-invasive to advanced/metastatic disease. Each of these clinical states is characterized by a unique pathogenesis, prognosis and approach to treatment. However, given the heterogeneity of urothelial carcinoma, differences in biology and outcomes exist not only among these clinical states but also within each state. Personalized medicine, also commonly referred to as individualized or stratified medicine, offers the potential to optimize treatment for a given patient, based on the ability to accurately predict prognosis, response to treatment and tolerability of treatment. This review will discuss recent efforts, current challenges and future opportunities, for the personalized management of urothelial carcinoma.",
keywords = "biomarker, bladder cancer, chemotherapy, neoadjuvant therapy, personalized medicine, urothelial carcinoma",
author = "Tsao, {Che Kai} and Gartrell, {Benjamin A.} and Oh, {William K.} and Galsky, {Matthew D.}",
year = "2012",
month = "12",
doi = "10.1586/era.12.141",
language = "English (US)",
volume = "12",
pages = "1537--1543",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "12",

}

TY - JOUR

T1 - Emerging personalized approaches for the management of advanced urothelial carcinoma

AU - Tsao, Che Kai

AU - Gartrell, Benjamin A.

AU - Oh, William K.

AU - Galsky, Matthew D.

PY - 2012/12

Y1 - 2012/12

N2 - Urothelial carcinoma of the bladder comprises a spectrum of illnesses ranging from nonmuscle-invasive to muscle-invasive to advanced/metastatic disease. Each of these clinical states is characterized by a unique pathogenesis, prognosis and approach to treatment. However, given the heterogeneity of urothelial carcinoma, differences in biology and outcomes exist not only among these clinical states but also within each state. Personalized medicine, also commonly referred to as individualized or stratified medicine, offers the potential to optimize treatment for a given patient, based on the ability to accurately predict prognosis, response to treatment and tolerability of treatment. This review will discuss recent efforts, current challenges and future opportunities, for the personalized management of urothelial carcinoma.

AB - Urothelial carcinoma of the bladder comprises a spectrum of illnesses ranging from nonmuscle-invasive to muscle-invasive to advanced/metastatic disease. Each of these clinical states is characterized by a unique pathogenesis, prognosis and approach to treatment. However, given the heterogeneity of urothelial carcinoma, differences in biology and outcomes exist not only among these clinical states but also within each state. Personalized medicine, also commonly referred to as individualized or stratified medicine, offers the potential to optimize treatment for a given patient, based on the ability to accurately predict prognosis, response to treatment and tolerability of treatment. This review will discuss recent efforts, current challenges and future opportunities, for the personalized management of urothelial carcinoma.

KW - biomarker

KW - bladder cancer

KW - chemotherapy

KW - neoadjuvant therapy

KW - personalized medicine

KW - urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84871501689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871501689&partnerID=8YFLogxK

U2 - 10.1586/era.12.141

DO - 10.1586/era.12.141

M3 - Article

VL - 12

SP - 1537

EP - 1543

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 12

ER -